Driehaus Capital Management LLC bought a new stake in BeiGene, Ltd. (NASDAQ:BGNE – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,185 shares of the company’s stock, valued at approximately $1,168,000.
Other institutional investors have also added to or reduced their stakes in the company. Swedbank AB bought a new position in BeiGene in the first quarter valued at $2,596,000. AIA Group Ltd boosted its position in BeiGene by 38.9% during the first quarter. AIA Group Ltd now owns 18,497 shares of the company’s stock valued at $2,893,000 after buying an additional 5,181 shares during the period. M&G Plc purchased a new stake in BeiGene during the first quarter valued at about $29,649,000. Van ECK Associates Corp boosted its position in BeiGene by 8.9% during the second quarter. Van ECK Associates Corp now owns 95,577 shares of the company’s stock valued at $13,636,000 after buying an additional 7,816 shares during the period. Finally, Barings LLC boosted its position in BeiGene by 66.4% during the second quarter. Barings LLC now owns 51,763 shares of the company’s stock valued at $7,385,000 after buying an additional 20,663 shares during the period. Institutional investors own 48.55% of the company’s stock.
Insiders Place Their Bets
In other BeiGene news, insider Titus B. Ball sold 137 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $189.94, for a total value of $26,021.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other BeiGene news, insider Titus B. Ball sold 137 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $189.94, for a total value of $26,021.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Chan Henry Lee sold 834 shares of the firm’s stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $160.57, for a total transaction of $133,915.38. The disclosure for this sale can be found here. Insiders sold 11,527 shares of company stock worth $2,214,263 over the last three months. Company insiders own 7.43% of the company’s stock.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on BGNE
BeiGene Stock Performance
BeiGene stock opened at $218.42 on Monday. The company has a current ratio of 1.98, a quick ratio of 1.75 and a debt-to-equity ratio of 0.06. The firm has a 50-day moving average of $187.99 and a 200-day moving average of $166.15. The firm has a market cap of $21.17 billion, a P/E ratio of -28.85 and a beta of 0.61. BeiGene, Ltd. has a 1-year low of $126.97 and a 1-year high of $223.96.
BeiGene (NASDAQ:BGNE – Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.27) by $1.12. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The company had revenue of $929.20 million during the quarter, compared to analyst estimates of $810.34 million. During the same period in the prior year, the business posted ($3.64) earnings per share. BeiGene’s revenue for the quarter was up 56.1% on a year-over-year basis. Sell-side analysts expect that BeiGene, Ltd. will post -5.13 EPS for the current year.
BeiGene Company Profile
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.
Read More
- Five stocks we like better than BeiGene
- Retail Stocks Investing, Explained
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- How to buy stock: A step-by-step guide for beginners
- CarMax’s Impressive Rally: What Investors Should Watch Next
- ESG Stocks, What Investors Should Know
- MarketBeat Week in Review – 9/23 – 9/27
Want to see what other hedge funds are holding BGNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeiGene, Ltd. (NASDAQ:BGNE – Free Report).
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.